ESOPHAGEAL ADENOCARCINOMA (EAC)
Clinical trials for ESOPHAGEAL ADENOCARCINOMA (EAC) explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL ADENOCARCINOMA (EAC) trials appear
Sign up with your email to follow new studies for ESOPHAGEAL ADENOCARCINOMA (EAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy boosts Chemo-Radiation in esophageal cancer trial
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy helps people with advanced esophageal cancer live longer without the disease getting worse. About 700 participants who cannot have surgery will receive either pembrolizumab …
Matched conditions: ESOPHAGEAL ADENOCARCINOMA (EAC)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 05:13 UTC
-
French study tracks Real-World survival of nivolumab combo for stomach cancer
Knowledge-focused OngoingThis study follows 208 adults in France with advanced or metastatic stomach, gastroesophageal junction, or esophageal cancer who are receiving nivolumab combined with chemotherapy as their first treatment. The main goal is to see how long patients live in real-world conditions. R…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA (EAC)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated May 22, 2026 14:04 UTC